Novel Inflammatory Marker in Dialysis Patients: YKL-40

Therapeutic Apheresis and Dialysis

Volumn 17, Issue 2, 2013, Pages 193-201

  Okyay, Gülay Ulusal ^a   Er, Ramazan Erdem ^a   Tekbudak, Merve Yasemin ^a   Paşaoǧlu, Özge ^a   Inal, Salih ^a   Öneç, Kürşad ^a   Paşaoǧlu, Hatice ^a   Altok, Kadriye ^a   Derici, Ülver ^a   Erten, Yasemin ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Chronic renal failure; Dialysis; Inflammation; YKL 40

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; GLYCOPROTEIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVITY C REACTIVE PROTEIN; INTERLEUKIN 6; SERUM ALBUMIN; UNCLASSIFIED DRUG; YKL 40 PROTEIN;

ADULT; AGING; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; LABORATORY TEST; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SMOKING;

ADIPOKINES; ADULT; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CREATININE; CROSS-SECTIONAL STUDIES; FEMALE; HEMOGLOBINS; HUMANS; INFLAMMATION; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; LECTINS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERITONEAL DIALYSIS; REGRESSION ANALYSIS; RENAL DIALYSIS; SERUM ALBUMIN;

EID: 84875809842     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2012.01141.x     Document Type: Article

References (40)

1. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697-701.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32:112-19.
3. Stenvinkel P, Heimbürger O, Paultre F etal. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-911.
4. Recio-Mayoral A, Banerjee D, Streather C, Kaski JC. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease-a cross-sectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis 2011;216:446-51.
5. Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 2003;14:1927-39.
6. deFilippi C, Wasserman S, Rosanio S etal. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003;290:353-9.
7. Menon V, Wang X, Greene T etal. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis 2003;42:44-52.
8. Davis R, Bansal V, Litinas E etal. Upregulation of inflammatory mediators in end-stage renal disease as measured using biochip array technology. Clin Appl Thromb Hemost 2011;17:218-23.
9. Kim SB, Min WK, Lee SK, Park JS, Hong CD, Yang WS. Persistent elevation of C-reactive protein and ischemic heart disease in patients with continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2002;39:342-6.
10. Wang AY, Wang M, Woo J etal. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004;15:2186-94.
11. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35:469-76.
12. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006;53:172-209.
13. Kucur M, Isman FK, Karadag B, Vural VA, Tavsanoglu S. Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis 2007;18:391-6.
14. Michelsen AE, Rathcke CN, Skjelland M etal. Increased YKL-40 expression in patients with carotid atherosclerosis. Atherosclerosis 2010;211:589-95.
15. Thomsen SB, Rathcke CN, Zerahn B, Vestergaard H. Increased levels of the calcification marker matrix Gla Protein and the inflammatory markers YKL-40 and CRP in patients with type 2 diabetes and ischemic heart disease. Cardiovasc Diabetol 2010;9:86-93.
16. Matsumoto T, Tsurumoto T. Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laboratory parameters. Clin Exp Rheumatol 2001;19:655-60.
17. Atreya R, Mudter J, Finotto S etal. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn's disease and experimental colitis in vivo. Nat Med 2000;6:583-8.
18. Nielsen AR, Plomgaard P, Krabbe KS, Johansen JS, Pedersen BK. IL-6, but not TNF-α, increases plasma YKL-40 in human subjects. Cytokine 2011;55:152-5.
19. Nordenbaek C, Johansen JS, Junker P, Borregaard N, Sørensen O, Price PA. YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. J Infect Dis 1999;180:1722-6.
20. Vind I, Johansen JS, Price PA, Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol 2003;38:599-605.
21. Johansen JS, Pedersen AN, Schroll M, Jørgensen T, Pedersen BK, Bruunsgaard H. High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality. Clin Exp Immunol 2008;151:260-6.
22. Mathiasen AB, Harutyunyan MJ, Jørgensen E etal. Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease. Scand J Clin Lab Invest 2011;71:439-47.
23. Catalán V, Gómez-Ambrosi J, Rodríguez A etal. Increased circulating and visceral adipose tissue expression levels of YKL-40 in obesity-associated type 2 diabetes are related to inflammation: impact of conventional weight loss and gastric bypass. J Clin Endocrinol Metab 2011;96:200-9.
24. Schiavon LL, Narciso-Schiavon JL, Carvalho Filho RJ etal. Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection. J Viral Hepat 2008;15:666-74.
25. Johansen JS, Hvolris J, Hansen M, Backer V, Lorenzen I, Price PA. Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 1996;35:553-9.
26. Johansen JS, Møller S, Price PA etal. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis? Scand J Gastroenterol 1997;32:582-90.
27. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998;54:627-36.
28. Beddhu S, Kaysen GA, Yan G etal. HEMO Study Group. Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis 2002;40:721-7.
29. Stenvinkel P, Heimbürger O, Lindholm B, Kaysen GA, Bergström J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis syndrome (MIA syndrome). Adv Ren Replace Ther 2003;10:332-45.
30. Stenvinkel P, Pecoits-Filho R, Lindholm B. Leptin, ghrelin, and proinflammatory cytokines: compounds with nutritional impact in chronic kidney disease? Adv Ren Replace Ther 2003;10:332-45.
31. Plata-Salamán CR. Cytokines and anorexia: a brief overview. Semin Oncol 1998;25:64-72.
32. Wei M, Bargman JM, Oreopoulos DG. Factors related to erythropoietin hypo-responsiveness in patients on chronic peritoneal dialysis. Int Urol Nephrol 2007;39:935-40.
33. Vaziri ND, Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif 2011;31:189-96.
34. Navab M, Hama SY, Cooke CJ etal. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000;41:1481-94.
35. Navab M, Hama SY, Anantharamaiah GM etal. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000;41:1495-508.
36. Navab M, Imes SS, Hama SY etal. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991;88:2039-46.
37. Irish A. Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 1998;137:133-9.
38. Bojesen SE, Johansen JS, Nordestgaard BG. Plasma YKL-40 levels in healthy subjects from the general population. Clin Chim Acta 2011;412:709-12.
39. Sakazaki Y, Hoshino T, Takei S etal. Overexpression of chitinase 3-like 1/YKL-40 in lung-specific IL-18-transgenic mice, smokers and COPD. PLoS ONE 2011;6:24177-85.
40. Matsuura H, Hartl D, Kang MJ etal. Role of breast regression protein-39 in the pathogenesis of cigarette smoke-induced inflammation and emphysema. Am J Respir Cell Mol Biol 2011;44:777-86.